29 research outputs found

    Modeling Hidden Nodes Collisions in Wireless Sensor Networks: Analysis Approach

    Full text link
    This paper studied both types of collisions. In this paper, we show that advocated solutions for coping with hidden node collisions are unsuitable for sensor networks. We model both types of collisions and derive closed-form formula giving the probability of hidden and visible node collisions. To reduce these collisions, we propose two solutions. The first one based on tuning the carrier sense threshold saves a substantial amount of collisions by reducing the number of hidden nodes. The second one based on adjusting the contention window size is complementary to the first one. It reduces the probability of overlapping transmissions, which reduces both collisions due to hidden and visible nodes. We validate and evaluate the performance of these solutions through simulations

    Truth and lies about the use of old drugs against COVID-19: have we learned the lesson? - Supplementary material

    No full text
    Supplementary Table 1. Association of methylation levels of CpG units of SLC19A1 promoter region and the clinical parameters of adult ALL patients Supplementary Table 2. Correlation analysis of methylation levels for CpG units of SLC19A1 promoter region and MTX concentrations in adult ALL patients Supplementary Table 3. Correlation analysis of methylation levels for CpG units of SLC19A1 promoter region and MTX elimination delay in adult ALL patients Supplementary Table 4. Association of methylation levels for CpG units of SLC19A1 promoter region and MTX toxicities in adult ALL patients Supplementary Table 5. Incidence of toxicities and MTX delayed excretion patients </p

    High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis

    No full text
    <div><p>The optimal dose, scheme, and clinical setting for Ara-C in acute myeloid leukemia (AML) treatment remain uncertain. In this study, we performed a meta-analysis to systematically assess the impact of high-dose cytarabine (HDAC) on AML therapy during the induction and consolidation stages. Twenty-two trials with a total of 5,945 <i>de</i><i>novo</i> AML patients were included in the meta-analysis. Only patients less than 60 year-old were included in the study. Using HDAC in induction therapy was beneficial for RFS (HR = 0.57; 95% CI, 0.35–0.93; <i>P</i> = 0.02) but not so for CR rate (HR = 1.01; 95% CI, 0.93–1.09; <i>P</i> = 0.88) and OS (HR = 0.83; 95% CI, 0.66–1.03; <i>P</i> = 0.1). In consolidation therapy, HDAC showed significant RFS benefits (HR = 0.67; 95% CI, 0.49–0.9; <i>P</i> = 0.008) especially for the favorable-risk group (HR = 0.38; 95% CI, 0.21–0.69; <i>P</i> = 0.001) compared with SDAC (standard dose cytarabine), although no OS advantage was observed (HR = 0.84; 95% CI, 0.55–1.27; <i>P</i> = 0.41). HDAC treatment seemed less effective than auto-BMT/allo-BMT treatment (HR = 1.66, 95% CI, 1.3–2.14; <i>P</i><0.0001) with similar OS. HDAC treatment led to lower relapse rate in induction and consolidation therapy than SDAC treatment, especially for the favorable-risk group. Auto-BMT/allo-BMT was more beneficial in prolonging RFS than HDAC.</p></div

    Effect of HDAC versus SDAC in induction therapy.

    No full text
    <p><b>A</b>: Effect of HDAC versus SDAC in induction therapy on CR rate. <b>B</b>: Overall survival benefit of HDAC in induction therapy. <b>C</b>: Relapse free survival benefit of HDAC in induction therapy.</p

    Relapse free survival benefit of HDAC in consolidation therapy.

    No full text
    <p><b>A</b>: Total relapse free survival benefit of HDAC in consolidation therapy. <b>B</b>: Relapse free survival benefit of different subgroups of HDAC in consolidation therapy.</p

    Characteristics of Included Studies for consolidation therapy.

    No full text
    <p>Note: ▴ S. Miyawaki et al, 2011 repeated the same trial of S, Ohtake et al, 2011.</p><p>BMT randomized trials were defined that if the patients didn’t have donors, they were randomized into auto-BMT and high-dosed Ara-C groups.</p><p>★analyze analyze <60 years the patients in each trial.</p><p>Abbreviations: NR, not reported; IDA, idarubicin; Ara-c, cytarabin; VP-16, etoposide; DNR, daunorubicin MCT, multiagent chemotherapy;</p><p>CTX, cyclophosphamide; MTZ, mitoxantrone; AZQ, diaziquone; 6-TG, thioguanine; AMS, amsacrine.</p><p>Characteristics of Included Studies for consolidation therapy.</p

    Characteristics of included Studies for induction therapy.

    No full text
    <p>Note: ▴ T. Büchner et al, 2009 repeated the same trial of T. Büchner et al, 2006.</p><p>analyze <60 years patients in each trial.</p><p>Abbreviations: NR, not reported; IDA, idarubicin; Ara-c, cytarabin; VP-16, etoposide; DNR, daunorubicin.</p><p>Characteristics of included Studies for induction therapy.</p

    Additional file 1: of Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells

    No full text
    Figure S1. Flow cytometry analysis of CD45+CD33+ leukemia cells in peripheral blood of 14 and 7 days before death of leukemia mice. Figure S2. FLT3 SFI of three cord blood CD34+ HSCs, five FLT3+ leukemia cell lines, and leukemia cells of ten AML patients were analyzed by flow cytometry. (PNG 1277 kb
    corecore